Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Hydrocodone Bitartrate 7 5 Mg"

00:37 EDT 29th July 2014 | BioPortfolio

Matching Channels

None

Matching News

FDA grants Priority Review designation for Purdue’s hydrocodone bitartrate

Privately held US drugmaker Purdue Pharma has been granted Priority Review designation by the US Food and Drug Administration for its once-daily, single-entity hydrocodone bitartrate tablet.

Purdue Pharma Announces Positive Phase 3 Clinical Trial Results of Hydrocodone Bitartrate ER Tablets

Stamford, CT – March 12, 2014 – Purdue Pharma L.P. announced that a Phase 3 study of an investigational extended-release formulation of hydrocodone bitartrate met its primary efficacy endpoint by...

Purdue gets FDA priority review designation for hydrocodone bitartrate tablets

The US Food and Drug Administration (FDA) has granted priority review designation for US-based Purdue Pharma's hydrocodone bitartrate extended-release tablets for treatment of chronic pain.

Purdue’s hydrocodone bitartrate tablets granted priority review designation

Purdue Pharma has been granted priority review designation by the US Food and Drug Administration (FDA) for its hydrocodone bitartrate extended-release tablets for treatment of chronic pain.

Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration seeking authorization to market a once-daily, single-entity hydrocodone bitartrate...

Update on Tamper-Proof Hydrocodone Products

Purdue and Zogenix report their progress in gaining approval for formulations of single-entity hydrocodone bitartrate that are difficult to misuse or abuse. Medscape Medical News

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology provi...

Novel Hydrocodone: 24-Hour Analgesia, Less Abuse Potential

Once-daily, extended-release hydrocodone bitartrate provides persistent pain relief in patients with chronic nonmalignant and nonneuropathic pain and also comes with abuse-deterrent properties. Meds...

Matching PubMed Articles

Purification and identification of impurities in vinorelbine bitartrate.

To investigate the chemical constituents of impurities in Vinorelbine Bitartrate.

Observations on the Urine Metabolic Profile of Codeine in Pain Patients.

This retrospective data analysis explored the relationship between codeine and its metabolites morphine, hydrocodone and hydromorphone. The objectives were: (i) to determine urine concentrations and m...

Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.

Infantile neuronal ceroid lipofuscinosis is a devastating neurodegenerative lysosomal storage disease caused by mutations in the gene (CLN1 or PPT1) encoding palmitoyl-protein thioesterase-1 (PPT1). W...

Extended-release hydrocodone (Zohydro) for pain.

Observation of improved adherence with frequent urine drug testing in patients with pain.

To determine the relationship between urine drug testing (UDT) frequency and patient adherence for prescribed buprenorphine, carisoprodol, fentanyl, hydrocodone, methadone, morphine, and oxycodone.

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement